Know What's Happening in BioTech

Sometimes Less Is More: Messier Nanoparticles May Actually Deliver Drugs More Effectively than Tightly Packed Ones
NewsFeb 21, 2026

Sometimes Less Is More: Messier Nanoparticles May Actually Deliver Drugs More Effectively than Tightly Packed Ones

Researchers at the University of Copenhagen unveiled a high‑throughput, single‑nanoparticle analysis that examined millions of lipid nanoparticles (LNPs) used for RNA delivery. The study identified two distinct LNP subpopulations—organized, onion‑layered particles and disordered, amorphous particles—and found the latter release their...

By Phys.org – Nanotechnology
It Seems Bad That Temu Is Selling Peptides
NewsFeb 21, 2026

It Seems Bad That Temu Is Selling Peptides

A recent Futurism report reveals that the low‑cost e‑commerce platform Temu is selling a variety of peptide products, including BPC‑157 and GLP‑1‑like compounds, at prices as low as $4. These peptides, marketed as muscle, skin, or cognitive boosters, are often...

By Futurism BioTech
GLP-1 Drugs Fail to Slow Cognitive Decline in Alzheimer’s Disease
BlogFeb 21, 2026

GLP-1 Drugs Fail to Slow Cognitive Decline in Alzheimer’s Disease

Recent randomized trials testing GLP‑1 receptor agonists such as semaglutide and liraglutide in Alzheimer’s disease patients found no measurable slowing of cognitive decline. Earlier post‑hoc and observational analyses had suggested roughly a 50 % reduction in dementia incidence, raising hopes of...

By The Peter Attia Drive / Articles
Science Corp. And Neurosoft Bioelectronics Announce Novel BCI Ecosystem Partnership
BlogFeb 21, 2026

Science Corp. And Neurosoft Bioelectronics Announce Novel BCI Ecosystem Partnership

Science Corporation and Neurosoft Bioelectronics have signed a multiyear, multimillion‑dollar partnership granting Neurosoft access to Science’s full‑stack clinical‑grade BCI tools, known as the Science BCI Ecosystem. The deal lets Neurosoft develop minimally invasive, fully implantable brain‑computer interfaces for tinnitus, epilepsy...

By HealthTech HotSpot
What Is a 'Seesaw Protein' That Switches Functions by Changing Shape?
NewsFeb 20, 2026

What Is a 'Seesaw Protein' That Switches Functions by Changing Shape?

Researchers at the Institute of Science Tokyo have engineered an artificial "seesaw protein" that alternates between a fluorescent marker and an enzymatic catalyst. The switch is controlled by a single amino‑acid change, pH shifts, or ligand binding, and only one...

By Phys.org – Biotechnology
Learning From FDA’s Moderna U-Turn
NewsFeb 20, 2026

Learning From FDA’s Moderna U-Turn

The FDA abruptly reversed its decision to approve Moderna’s mRNA‑based flu vaccine after the White House intervened, sparking intense discussion in biotech boardrooms. The reversal was driven by political considerations rather than new scientific data, underscoring the agency’s vulnerability to...

By BioCentury
Novartis Breaks Ground on $23B Biomedical Research Hub in San Diego
BlogFeb 20, 2026

Novartis Breaks Ground on $23B Biomedical Research Hub in San Diego

Novartis began construction of a new biomedical research hub in San Diego. The 466,000‑sq‑ft center, part of a $23 billion US R&D and manufacturing program, will house about 1,000 researchers and target neuroscience, oncology, global health, and age‑related diseases. Scheduled to...

By Xtalks – Biotech Blogs
How to Avoid a Fall by Balancing Cost and Performance in Drug Discovery
NewsFeb 20, 2026

How to Avoid a Fall by Balancing Cost and Performance in Drug Discovery

Balancing cost and performance in drug discovery requires a hybrid engineering‑led approach that combines on‑premise HPC with scalable cloud resources. Uncontrolled cloud scaling can drive unpredictable expenses, while pure on‑premise systems demand high upfront capital and maintenance. By implementing disciplined...

By GEN (Genetic Engineering & Biotechnology News)
Altesa BioSciences Raises $75M Series B
NewsFeb 20, 2026

Altesa BioSciences Raises $75M Series B

Altesa BioSciences announced an oversubscribed $75 million Series B round, led by Forbion with participation from Sanofi and existing backers Medicxi, Pitango, and Atlantic Partners. The financing will support the development of its lead candidate, vapendavir, targeting viral-driven exacerbations in COPD and...

By VC News Daily
Topical Adquey (Difamilast) Wins FDA Approval for Atopic Dermatitis
BlogFeb 20, 2026

Topical Adquey (Difamilast) Wins FDA Approval for Atopic Dermatitis

The U.S. Food and Drug Administration has granted approval to Adquey, a 1% difamilast topical ointment, for the treatment of mild-to-moderate atopic dermatitis in patients two years and older. Developed by Otsuka and licensed to Acrotech Biopharma, the product is...

By Xtalks – Biotech Blogs
5-Day Preoperative Radiotherapy in High-Risk STS Shows Manageable Toxicity
NewsFeb 20, 2026

5-Day Preoperative Radiotherapy in High-Risk STS Shows Manageable Toxicity

A phase‑2 single‑center trial evaluated a five‑day pre‑operative radiotherapy schedule in 110 patients with high‑risk soft‑tissue sarcoma. At two‑year follow‑up, grade ≥ 2 radiation‑related toxicities were observed in 14 of 74 evaluable patients, with lower rates in the extension cohort. Major wound...

By AJMC (The American Journal of Managed Care)
At an Inflection Point in HIV Science: Nicolas Chomont, PhD, Looks Ahead to CROI 2026
NewsFeb 20, 2026

At an Inflection Point in HIV Science: Nicolas Chomont, PhD, Looks Ahead to CROI 2026

Nicolas Chomont, chair of CROI 2026’s scientific program, previewed the conference’s focus on emerging HIV research, including treatment, cure, and vaccine advances. The meeting will showcase extensive data on long‑acting antiretroviral therapies and address funding constraints affecting global HIV initiatives....

By AJMC (The American Journal of Managed Care)
Ten63 Therapeutics Secures New Funding
NewsFeb 20, 2026

Ten63 Therapeutics Secures New Funding

Ten63 Therapeutics, an AI‑driven drug‑discovery firm spun out of Duke and TTIC, announced a strategic investment from Chugai Venture Fund and the Bill & Melinda Gates Foundation, bringing total capital to over $45 million. The company leverages its BEYOND generative‑chemistry platform...

By VC News Daily
FDA Cracks Down as Novo Sues Hims over Semaglutide
SocialFeb 20, 2026

FDA Cracks Down as Novo Sues Hims over Semaglutide

This is the first reference which I heard directly from FDA commissioner Dr. Marty Makary regarding $HIMS, $NVO 🧵👇and the recent legal actions that the HHS had initiated against HIMs and Hers. When he was asked by @annikakimc - @CNBC’s...

By Yair Einhorn
Hormone-Regulated Immune Cells Implicated in Longer Lasting Pain in Women
NewsFeb 20, 2026

Hormone-Regulated Immune Cells Implicated in Longer Lasting Pain in Women

Researchers at Michigan State University discovered that hormone‑regulated monocytes producing interleukin‑10 (IL‑10) drive faster pain resolution in males. In mouse models, testosterone‑dependent IL‑10+ monocytes cleared inflammatory pain more quickly, while females exhibited fewer of these cells and prolonged pain. Human...

By GEN (Genetic Engineering & Biotechnology News)
To What Degree Does Cytomegalovirus Contribute to Neurodegenerative Conditions?
BlogFeb 20, 2026

To What Degree Does Cytomegalovirus Contribute to Neurodegenerative Conditions?

Cytomegalovirus (CMV) infection, prevalent in most adults, increasingly appears linked to neurodegenerative processes. Large cohort studies show higher CMV IgG levels correlate with accelerated cognitive decline, and post‑mortem analyses detect CMV DNA in a majority of vascular dementia brains. Animal...

By Fight Aging!
New Insights Into How Bacteria Control DNA Synthesis Open the Door to Next Generation Antimicrobials
NewsFeb 20, 2026

New Insights Into How Bacteria Control DNA Synthesis Open the Door to Next Generation Antimicrobials

Researchers have solved the crystal structure of the bacterial transcriptional regulator NrdR and shown how its assembly shifts in response to ATP and dATP, directly controlling ribonucleotide reductase (RNR) gene expression. The work, performed on Escherichia coli and Pseudomonas aeruginosa,...

By Phys.org – Biotechnology
Kansas City Launches Integrated Theranostics Platform Partnership
NewsFeb 20, 2026

Kansas City Launches Integrated Theranostics Platform Partnership

A public‑private partnership between the University of Kansas Health System, KU Medical Center, Children’s Mercy and Bold Advanced Medical Future (BAMF) Health is launching an integrated theranostics platform in Kansas City. The center will combine molecular imaging, radiopharmaceutical production, clinical...

By MobiHealthNews (HIMSS Media)
In the Clinic for Feb. 20, 2026
NewsFeb 20, 2026

In the Clinic for Feb. 20, 2026

The February 20 2026 "In the Clinic" roundup aggregates a broad set of industry snapshots, special reports, and infographics covering biopharma, medical technology, and emerging research areas. It links to data on mRNA vaccine research, China’s GLP‑1 market, pulsed‑field ablation for atrial...

By BioWorld (Citeline) – Featured Feeds
Generic Drugs Forum (GDF) 2026 - 04/22/2026
NewsFeb 20, 2026

Generic Drugs Forum (GDF) 2026 - 04/22/2026

On April 22‑23, 2026, the FDA’s Center for Drug Evaluation and Research hosted the annual Generic Drugs Forum at its White Oak Campus, with a virtual option via Adobe Connect. The two‑day event gathered generic drug developers, consultants, and regulatory...

By FDA
Macrophage Phenotype–Dependent Protein Corona Formation Governs Ligand Accessibility and Immune Clearance of Biomimetic Nanoparticles
NewsFeb 20, 2026

Macrophage Phenotype–Dependent Protein Corona Formation Governs Ligand Accessibility and Immune Clearance of Biomimetic Nanoparticles

Researchers coated magnetic silica nanoparticles with membranes from naïve (M0), classically activated (M1) and alternatively activated (M2) macrophages to study phenotype‑dependent protein corona formation. Proteomic analysis showed M0‑derived membranes adsorbed the fewest opsonins (C3, IgG, IgM) and triggered the lowest...

By Small (Wiley)
From Junk Science (Largely Non-Political) to Junk Medical Treatments (Mostly Associated with the Far-Right):  A Financial Connection
BlogFeb 20, 2026

From Junk Science (Largely Non-Political) to Junk Medical Treatments (Mostly Associated with the Far-Right): A Financial Connection

Paul Krugman highlights a growing financial link between the multi‑billion‑dollar wellness industry and right‑wing extremist movements. He notes that U.S. spending on wellness reaches roughly $500 billion annually, with nutritional supplements alone accounting for about $70 billion, while regulators like the FDA...

By Statistical Modeling, Causal Inference, and Social Science
A Quercetin Nanocarrier‐Loaded Dual Network Injectable Hydrogel for Mesenchymal Stem Cells (MSCs) Delivery Targeting Osteoarthritis
NewsFeb 20, 2026

A Quercetin Nanocarrier‐Loaded Dual Network Injectable Hydrogel for Mesenchymal Stem Cells (MSCs) Delivery Targeting Osteoarthritis

Researchers have created an injectable dual‑network hydrogel composed of gelatin methacrylate and κ‑carrageenan that embeds quercetin‑loaded PLGA nanoparticles for mesenchymal stem cell (MSC) delivery in osteoarthritis (OA). The antioxidant hydrogel scavenges reactive oxygen species, reprograms M1 macrophages to an anti‑inflammatory...

By Small (Wiley)
STAT+: Pharmalittle: We’re Reading About an FDA Official’s Speech, a Grail Cancer Blood Test, and Much More
NewsFeb 20, 2026

STAT+: Pharmalittle: We’re Reading About an FDA Official’s Speech, a Grail Cancer Blood Test, and Much More

FDA drug‑center head Tracy Beth Høeg used her first staff address to flag two priority areas: the safety of antidepressants taken during pregnancy and the use of monoclonal antibodies that protect infants from RSV. She also signaled a continued interest...

By STAT News — Pharma
Exercise‑induced Liver Enzyme GPLD1 Restores Memory, Boosts Vascular Health
SocialFeb 20, 2026

Exercise‑induced Liver Enzyme GPLD1 Restores Memory, Boosts Vascular Health

Liver enzyme GPLD1 produced during exercise reverses aging- and Alzheimer’s-related memory loss by improving vascular health https://www.cell.com/cell/fulltext/S0092-8674%2826%2900111-X

By David Sinclair
FDA Starts Review of Regeneron's Drug for Rare Disease FOP
NewsFeb 20, 2026

FDA Starts Review of Regeneron's Drug for Rare Disease FOP

The FDA has placed Regeneron's anti‑activin A antibody garetosmab under priority review, with a decision expected by August. Phase 3 OPTIMA data showed a 94% reduction in new heterotopic ossification lesions at the lower dose and a 90% reduction at the higher...

By pharmaphorum
Inside Oxford’s Biotech Hub: A Scientific Powerhouse Situated in the U.K.’s Golden Triangle
NewsFeb 20, 2026

Inside Oxford’s Biotech Hub: A Scientific Powerhouse Situated in the U.K.’s Golden Triangle

Oxford has cemented its status as a leading European biotech hub, anchored by the University of Oxford’s deep biomedical expertise and a thriving spin‑out ecosystem. The Oxford Science Park now houses nearly 100 life‑science companies, while the £1.2 bn Oxford North...

By Labiotech.eu
Evolving Frontline Treatment Strategies in Diffuse Large B-Cell Lymphoma
NewsFeb 20, 2026

Evolving Frontline Treatment Strategies in Diffuse Large B-Cell Lymphoma

Frontline treatment of diffuse large B‑cell lymphoma (DLBCL) is shifting from traditional R‑CHOP toward targeted and bispecific antibody‑based regimens. The POLARIX phase‑3 trial demonstrated that Pola‑R‑CHP improves progression‑free survival, particularly in activated‑B‑cell (ABC) disease and older patients. Early phase studies...

By Pharmacy Times
Nanozyme Aptasensor: A Breakthrough in S. Aureus Diagnostics
NewsFeb 20, 2026

Nanozyme Aptasensor: A Breakthrough in S. Aureus Diagnostics

Researchers have unveiled a nanozyme‑aptamer colorimetric array that classifies Staphylococcus aureus strains with 100% accuracy, including methicillin‑resistant variants. The platform couples gold‑nanoparticle nanozymes with four strain‑specific aptamers, producing distinct color fingerprints that are decoded by hierarchical clustering and linear discriminant...

By AZoNano
No One-Trick Pony in Oncology, Merck’s Cancer Footprint Is Expanding
NewsFeb 20, 2026

No One-Trick Pony in Oncology, Merck’s Cancer Footprint Is Expanding

Merck is expanding beyond its flagship Keytruda by investing in diverse oncology platforms. In 2024 it spent $700 million on a bispecific candidate from Curon and $680 million to acquire Harpoon Therapeutics, bolstering its T‑cell engager portfolio. The company is also advancing...

By PharmaVoice
FDA Approves Acalabrutinib with Venetoclax for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NewsFeb 20, 2026

FDA Approves Acalabrutinib with Venetoclax for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The FDA approved a fixed‑dose combination of acalabrutinib (Calquence) and venetoclax (Venclexta) for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. The decision is based on the AMPLIFY trial, which showed a 35% reduction in progression‑free survival risk compared...

By FDA
The US FDA Accepts Roche’s Giredestrant NDA for ESR1-Mutated, ER-Positive Advanced Breast Cancer
NewsFeb 20, 2026

The US FDA Accepts Roche’s Giredestrant NDA for ESR1-Mutated, ER-Positive Advanced Breast Cancer

The U.S. FDA has accepted Roche’s new drug application for giredestrant combined with everolimus to treat ER‑positive, HER2‑negative, ESR1‑mutated advanced breast cancer. Phase III evERA data show a 44% reduction in disease progression or death overall and a 62% reduction in...

By PharmaShots
UK Firm Steps in to Ease Medicine Supply Crisis in NHS
NewsFeb 20, 2026

UK Firm Steps in to Ease Medicine Supply Crisis in NHS

A shortage of bone cement from German supplier Heraeus Medical threatens NHS orthopaedic surgeries, potentially lasting two months. NHS England has asked trusts to prioritise emergency joint replacements, leaving elective patients at risk. UK‑based Biocomposites accelerated the launch of its...

By pharmaphorum
Novartis to Divest India Unit to Private Equity-Led Consortium for $159M
NewsFeb 20, 2026

Novartis to Divest India Unit to Private Equity-Led Consortium for $159M

Novartis announced the sale of its majority stake in its Indian generics and prescription business to a private‑equity‑led consortium for $159 million. The transaction transfers control of a portfolio that includes both off‑patent generics and branded medicines to the buyers. The...

By Endpoints News
Revealing Remarkable Genomic Architecture in Embryonic Reproductive Cells Prior to Sperm and Egg Development
NewsFeb 20, 2026

Revealing Remarkable Genomic Architecture in Embryonic Reproductive Cells Prior to Sperm and Egg Development

Researchers led by Dr. Tien‑Chi Huang discovered a dramatic three‑dimensional reorganization of genome architecture in mouse and human embryonic germ cells as they enter meiosis. Centromeres relocate from the nuclear interior to the periphery, accompanied by reduced compartmentalization and increased...

By Bioengineer.org
Levetiracetam Reduces Amyloid-Β Production in the Brain
BlogFeb 20, 2026

Levetiracetam Reduces Amyloid-Β Production in the Brain

Researchers report that the FDA‑approved antiepileptic levetiracetam reduces amyloid‑β42 production in mouse models of Alzheimer’s disease. The drug redirects amyloid precursor protein processing toward the non‑amyloidogenic pathway by modifying synaptic vesicle cycling and increasing surface APP expression. Mass‑spectrometry and electrophysiology...

By Fight Aging!
Aging Is Often Overlooked in Mouse Models of Age-Related Conditions
BlogFeb 20, 2026

Aging Is Often Overlooked in Mouse Models of Age-Related Conditions

Researchers increasingly rely on rapid, toxic mouse models that sideline the natural aging process, even though age is the chief risk factor for many diseases. In Parkinson's disease research, most pre‑clinical studies still use young rodents, obscuring how biological aging...

By Fight Aging!
Pharma Pulse: J&J’s $1B Cell Therapy Hub and Hims & Hers’ Global Expansion
BlogFeb 20, 2026

Pharma Pulse: J&J’s $1B Cell Therapy Hub and Hims & Hers’ Global Expansion

Johnson & Johnson announced a $1 billion investment to build a next‑generation cell‑therapy manufacturing facility in Montgomery County, Pennsylvania, slated to support 500 skilled jobs. The hub is a key element of J&J’s $55 billion U.S. manufacturing, R&D, and technology strategy. Meanwhile,...

By Pharmaceutical Commerce (independent trade)
NKTR’s Alopecia Areata Play: Market Misprices Massive Upside
SocialFeb 20, 2026

NKTR’s Alopecia Areata Play: Market Misprices Massive Upside

Ok, so I have finally gotten around to writing out my updated thoughts/thesis on $NKTR. Link in this post. I'm about as bullish on the stock now as I've ever been. The document is very long (sorry, but it's free...give me...

By Adam May
Monocyte IL‑10 Explains Sex Differences in Pain Duration
SocialFeb 20, 2026

Monocyte IL‑10 Explains Sex Differences in Pain Duration

Sex differences in pain duration Finding interleukin-10 from monocytes as an/the explanation (in the experimental model and people) @SciImmunology https://t.co/fOsciwav7Y

By Eric Topol
Ex-Novartis CMO John Tsai Joins Daiichi Sankyo
NewsFeb 20, 2026

Ex-Novartis CMO John Tsai Joins Daiichi Sankyo

Daiichi Sankyo appointed former Novartis chief medical officer John Tsai as its new CMO, succeeding Ken Takeshita after a five‑year tenure. Tsai brings a record of launching 160 projects and 15 regulatory approvals, including Zolgensma and Pluvicto, and recent experience leading biotech...

By pharmaphorum
Nasal Mucosa Targeted for Universal Respiratory Vaccine
SocialFeb 20, 2026

Nasal Mucosa Targeted for Universal Respiratory Vaccine

How to get a universal vaccine vs respiratory threats? Block via the nasal mucosa @ScienceMagazine https://t.co/IjCkbF05LB @NatRevImmunol https://t.co/2W7SZ1fHSR https://t.co/XcEzcMeXrB

By Eric Topol
New Drug Discoveries Target Cancer and Autoimmunity
SocialFeb 20, 2026

New Drug Discoveries Target Cancer and Autoimmunity

Discovering Drugs for Cancer and Autoimmunity. Listen to @Satpathology on The Long Run podcast. Sponsored by @AlphaSenseInc Dash Bio. https://t.co/02keVFdqzj

By Luke Timmerman
NexEos Bio Receives US FDA IND Clearance to Advance NTX-1024 Into P-II/III Study for Vernal Keratoconjunctivitis
NewsFeb 20, 2026

NexEos Bio Receives US FDA IND Clearance to Advance NTX-1024 Into P-II/III Study for Vernal Keratoconjunctivitis

U.S. FDA has granted IND clearance for NexEos Bio’s ophthalmic solution NTX-1024, allowing the company to commence a combined Phase II/III clinical trial in vernal keratoconjunctivitis (VKC). The upcoming study will assess safety and efficacy after an open‑label investigator‑initiated trial...

By PharmaShots
Lymphopenia Reversal Won’t Secure Anktiva FDA Approval
SocialFeb 20, 2026

Lymphopenia Reversal Won’t Secure Anktiva FDA Approval

Reversal of lymphopenia is not an acceptable endpoint for Anktiva FDA approval. $IBRX could file but if it did, the application would be rejected.

By Adam Feuerstein
Cyborg Islet-Cell Implant Boosts Precision Diabetes Therapy
SocialFeb 20, 2026

Cyborg Islet-Cell Implant Boosts Precision Diabetes Therapy

A cyborg pancreatic islet-cell implant takes the stem cell strategy to a new level of precision and potential future therapy for T1 diabetes @ScienceMagazine https://t.co/gkmsrzU1e4 https://t.co/qgegRPlEIl

By Eric Topol
Neutrophil Phenotypes and Spatial Patterns Mapped in Colorectal Cancer
SocialFeb 20, 2026

Neutrophil Phenotypes and Spatial Patterns Mapped in Colorectal Cancer

Single-cell integration and multi-modal profiling reveals phenotypes and spatial organization of neutrophils in colorectal cancer https://t.co/0FLusa7vuB https://t.co/8MswWoLhCa

By Ming Tang
Screening Cuts Advanced Colon Cancer, Boosts Early Detection
SocialFeb 20, 2026

Screening Cuts Advanced Colon Cancer, Boosts Early Detection

Screening works for colon cancer. Largest trial ever done. Today @NatureMedicine A randomized trial of colon cancer screening by colonoscopy or occult blood (FIT) vs control in nearly 280,000 participants showed signficantly more early diagnosis (stage I-II) and less stage...

By Eric Topol
AZN's Calquence + Venetoclax Approved for CLL Treatment
SocialFeb 20, 2026

AZN's Calquence + Venetoclax Approved for CLL Treatment

#AZN Calquence combined with Venetoclax approved in US for treating Adults with Chronic Lymphocytic Leukaemia in a particular form.

By WheelieDealer